This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tuesday's Small-Cap Winners & Losers

Amrep (AXR - Get Report) was higher after it said second-quarter net income more than tripled year over year. The company earned $16.1 million, or $2.42 a share, for its latest second quarter, up from $5.1 million and 76 cents a share a year ago. Revenue climbed to $56.1 million from $34.8 million last year. Shares of Amrep rose 13.7% to $100.

Micromet (MITI) advanced after it amended its agreement with Serono (SRA) to develop adecatumumab.

Micromet will continue to have operational responsibility for the current Phase 1b trial to evaluate the combination of adecatumumab and docetaxel in patients with metastatic breast cancer, and a new Phase 1 monotherapy study for the treatment of patients with solid tumors planned to begin in 2007. Serono will reimburse Micromet for its costs incurred in connection with the development program. Shares of Micromet were climbing nearly 12% to $3.35.

Wireless Telecom Group (WTT - Get Report) was gaining on word one of its units unveiled TD-SCDMA call-mode capability on its flagship 4400 Mobile-Phone Tester Series in support of China's planned 3G deployment.

The development makes the Willtek 4400 the industry's first mobile-phone tester that integrates all of the standard 3G technologies, including UMTS/WCDMA, CDMA2000/1xEVDO, and TD-SCDMA. The product also supports the standard 2G technologies of both GSM/GPRS/EDGE and cdmaOne. Shares of Wireless Telecom were up 11% to $2.93.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs